ORIGINAL PAPER
Correlations of miR-1290 and miR-191-5p with laboratory parameters
as a useful test to differentiate pancreatic cancer from chronic pancreatitis: preliminary study
1
Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland
2
Department of Gastroenterology with Endoscopic Unit, Medical University of Lublin, Lublin, Poland
3
Department of Medical Chemistry, Medical University of Lublin, Lublin, Poland
Submission date: 2023-03-08
Final revision date: 2023-04-30
Acceptance date: 2023-04-30
Publication date: 2023-06-30
Medical Studies 2023;39(2):114-121
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Accurate differential diagnosis between chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC) is still problematic. Difficulties arise from the fact that the imaging techniques, clinical symptoms, and laboratory parameters of these 2 diseases are similar. Therefore, non-invasive markers to clearly distinguish between these 2 disorders are urgently needed, and microRNAs (miRNAs) seem to be the most promising biomarkers, because of their tissue specificity, stability in different biofluids, and easy detection.
Aim of the research:
To evaluate the usefulness of the measurement of selected miRNAs and basic clinical parameters as a test for differentiating PDAC from CP.
Material and methods:
The expression of miR-21-5p, miR-23a-3p, miR-155-5p, miR-191-5p, miR-196a-5p, miR-205-5p, and miR-1290 was assessed in 74 serum samples (PDAC n = 26, CP n = 34, and the control group n = 14) by reverse transcription-quantitative PCR (RT-qPCR). Correlations between the levels of miRNAs and pancreatic lipase, amylase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), g-glutamyltranspeptidase (GGTP), haemoglobin (Hb), bilirubin, C-reactive protein (CRP), and CA19-9 were analysed in 3 groups.
Results:
We found that 2 combinations of miRNAs with blood parameters had diagnostic value. In PDAC the expression of miR-1290 positively correlated with GGTP activity (p = 0.029, rs = 0.487) and CA 19-9 level (p = 0.026, rs = 0.464), while in CP patients miR-191-5p expression was negatively correlated with amylase (p = 0.018, rs = –0.408) and CRP (p = 0.023, rs = –0.394). No statistically significant correlations were noticed between miRNAs and clinical parameters in the control group.
Conclusions:
The combination of miR-191-5p with CRP and amylase characterized CP, while miR-1290 with GGTP and CA 19-9 was specific for PDAC. These non-invasive tools can help to differentiate PDAC from CP.
Accurate differential diagnosis between chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC) is still problematic. Difficulties arise from the fact that the imaging techniques, clinical symptoms, and laboratory parameters of these 2 diseases are similar. Therefore, non-invasive markers to clearly distinguish between these 2 disorders are urgently needed, and microRNAs (miRNAs) seem to be the most promising biomarkers, because of their tissue specificity, stability in different biofluids, and easy detection.
Aim of the research:
To evaluate the usefulness of the measurement of selected miRNAs and basic clinical parameters as a test for differentiating PDAC from CP.
Material and methods:
The expression of miR-21-5p, miR-23a-3p, miR-155-5p, miR-191-5p, miR-196a-5p, miR-205-5p, and miR-1290 was assessed in 74 serum samples (PDAC n = 26, CP n = 34, and the control group n = 14) by reverse transcription-quantitative PCR (RT-qPCR). Correlations between the levels of miRNAs and pancreatic lipase, amylase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), g-glutamyltranspeptidase (GGTP), haemoglobin (Hb), bilirubin, C-reactive protein (CRP), and CA19-9 were analysed in 3 groups.
Results:
We found that 2 combinations of miRNAs with blood parameters had diagnostic value. In PDAC the expression of miR-1290 positively correlated with GGTP activity (p = 0.029, rs = 0.487) and CA 19-9 level (p = 0.026, rs = 0.464), while in CP patients miR-191-5p expression was negatively correlated with amylase (p = 0.018, rs = –0.408) and CRP (p = 0.023, rs = –0.394). No statistically significant correlations were noticed between miRNAs and clinical parameters in the control group.
Conclusions:
The combination of miR-191-5p with CRP and amylase characterized CP, while miR-1290 with GGTP and CA 19-9 was specific for PDAC. These non-invasive tools can help to differentiate PDAC from CP.
REFERENCES (55)
1.
De La Iglesia-García D, Huang W, Szatmary P, Baston-Rey I, Gonzalez-Lopez J, Prada-Ramallal G, Mukherjee R, Nu- nes QM, Domínguez-Muñoz JE, Sutton R; NIHR Pancreas Biomedical Research Unit Patient Advisory Group. Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-Analysis. Gut 2017; 66: 1474-1486.
2.
Hart PA, Conwell DL. Chronic pancreatitis: managing a difficult disease. Am J Gastroenterol 2020; 115: 49-55.
3.
Lew D, Afghani E, Pandol S. Chronic pancreatitis: current status and challenges for prevention and treatment. Dig Dis Sci 2017; 62: 1702-1712.
4.
Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet 2020; 395: 2008-2020.
5.
Kirkegård J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis. Am J Gastroenterol 2017; 112: 1366-1372.
6.
Perusina Lanfranca M, Zhang Y, Girgis A, Kasselman S, Lazarus J, Kryczek I, Delrosario L, Rhim A, Koneva L, Sartor M, Sun L, Halbrook C, Nathan H, Shi J, Crawford HC, di Magliano MP, Zou W, Frankel TL. Interleukin 22 signaling regulates acinar cell plasticity to promote pancreatic tumor development in mice. Gastroenterology 2020; 158: 1417-1432.
7.
Lippi G, Mattiuzzi C. The global burden of pancreatic cancer. Arch Med Sci 2020; 16: 820-824.
8.
Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 2019; 10: 10-27.
9.
Wolske KM, Ponnatapura J, Kolokythas O, Burke LMB, Tappouni R, Lalwani N. Chronic pancreatitis or pancreatic tumor? A problem-solving approach. Radiographics 2019; 39: 1965-1982.
10.
Silovs A, Strumfa I, Riekstins R, Simtniece Z, Vanags A, Gardovskis J. Systemic inflammatory response in pancreatic ductal adenocarcinoma. In: Advances in Pancreatic Cancer. Rodrigo L (ed.). IntechOpen 2018.
11.
Ghassem-Zadeh S, Hufnagel K, Bauer A, Frossard JL, Yoshida M, Kutsumi H, Acha-Orbea H, Neulinger- Muñoz M, Vey J, Eckert C, Strobel O, Hoheisel JD, Felix K. Novel autoantibody signatures in sera of patients with pancreatic cancer, chronic pancreatitis and autoimmune pancreatitis: a protein microarray profiling approach. Int J Mol Sci 2020; 21: 2403.
12.
Zheng Z, Chen Y, Tan C, Ke N, Du B, Liu X. Risk of pancreatic cancer in patients undergoing surgery for chronic pancreatitis. BMC Surg 2019; 19: 83.
13.
Filipów S, Łaczmański Ł. Blood circulating miRNAs as cancer biomarkers for diagnosis and surgical treatment response. Front Genet 2019; 10: 169.
14.
Zhao C, Sun X, Li L. Biogenesis and function of extracellular mirnas. ExRNA 2019; 1: 38.
15.
Guz M, Jeleniewicz W, Cybulski M, Kozicka J, Kurzepa J, Mądro A. Serum mir-210-3p can be used to differentiate between patients with pancreatic ductal adenocarcinoma and chronic pancreatitis. Biomed Reports 2020; 14: 10.
16.
Tsai HJ, Chang JS. Environmental risk factors of pancreatic cancer. J Clin Med 2019; 8: 1427.
17.
Allen MD, Jones LJ. The role of inflammation in progression of breast cancer: friend or foe? (Review). Int J Oncol 2015; 47: 797-805.
18.
Chakraborty C, Sharma AR, Sharma G, Lee SS. The interplay among miRNAs, major cytokines, and cancer-related inflammation. Mol Ther Nucleic Acids 2020; 20: 606-620.
19.
Michels N, van Aart C, Morisse J, Mullee A, Huybrechts I. Chronic inflammation towards cancer incidence: a systematic review and meta-analysis of epidemiological studies. Crit Rev Oncol Hematol 2021; 157: 103177.
20.
Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 2019; 51: 27-41.
21.
Nguyen L, Schilling D, Dobiasch S, Raulefs S, Santiago Franco M, Buschmann D, Pfaffl MW, Schmid TE, Combs SE. The emerging role of miRNAs for the radiation treatment of pancreatic cancer. Cancers 2020; 12: 3703.
22.
Xin L, Gao J, Wang D, Lin JH, Liao Z, Ji JT, Du TT, Jiang F, Hu LH. Novel blood-based microRNA biomarker panel for early diagnosis of chronic pancreatitis. Sci Rep 2017; 7: 40019.
23.
Lemberger M, Loewenstein S, Lubezky N, Nizri E, Pasmanik-Chor M, Barazovsky E, Klausner JM, Lahat G. MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis. Oncotarget 2019; 10: 2644-2656.
24.
Gablo N, Trachtova K, Prochazka V, Hlavsa J, Grolich T, Kiss I, Srovnal J, Rehulkova A, Lovecek M, Skalicky P, Berindan-Neagoe I, Kala Z, Slaby O. Identification and validation of circulating micrornas as prognostic biomarkers in pancreatic ductal adenocarcinoma patients undergoing surgical resection. J Clin Med 2020; 9: 2440.
25.
Meng S, Wang H, Xue D, Zhang W. Screening and validation of differentially expressed extracellular miRNAs in acute pancreatitis. Mol Med Rep 2017; 16: 6412-6418.
26.
Chhatriya B, Sarkar P, Nath D, Ray S, Das K, Mohapa- tra SK, Goswami S. Pilot study identifying circulating miRNA signature specific to alcoholic chronic pancreatitis and its implication on alcohol-mediated pancreatic tissue injury. JGH Open 2020; 4: 1079-1087.
27.
Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, Suciu N, Cretoiu SM, Voinea SC. miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells 2020; 9: 276.
28.
Batsios G, Najac C, Cao P, Viswanath P, Subramani E, Saito Y, Gillespie AM, Yoshihara HAI, Larson P, Sando S, Ro- nen SM. In vivo detection of -glutamyl-transferase up-regulation in glioma using hyperpolarized -glutamyl-[1-13C]glycine. Sci Rep 2020; 10: 6244.
29.
Yardim Akaydin S, Miser Salihoglu E, Gelen Gungor D, Karanlik H, Demokan S. Correlation between gamma-glutamyl transferase activity and glutathione levels in molecular subgroups of Breast Cancer. Eur J Breast Heal 2020; 16: 72-76.
30.
Xiao Y, Yang H, Lu J, Li D, Xu C, Risch HA. Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer. BMC Cancer 2019; 19: 1020.
31.
Li S, Xu H, Wu C, Wang W, Jin W, Gao H, Li H, Zhang S, Xu J, Zhang W, Xu S, Li T, Ni Q, Yu X, Liu L. Prognostic value of -glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Cancer Med 2019; 8: 572-584.
32.
Solt LA, May MJ. The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol Res 2008; 42: 3-18.
33.
Ta N, Huang X, Zheng K, Zhang Y, Gao Y, Deng L, Zhang B, Jiang H, Zheng J. MiRNA-1290 promotes aggressiveness in pancreatic ductal adenocarcinoma by targeting IKK1. Cell Physiol Biochem 2018; 51: 711-728.
34.
Azizian A, Rühlmann F, Krause T, Bernhardt M, Jo P, König A, Kleiß M, Leha A, Ghadimi M, Gaedcke J. CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep 2020; 10: 1332.
35.
Kim S, Park BK, Seo JH, Choi J, Choi JW, Lee CK, Chung JB, Park Y, Kim DW. Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases. Sci Rep 2020; 10: 8820.
36.
Dasgupta A, Wahed A. Clinical Chemistry, Immunology and Laboratory Quality Control. Clinical Chemistry, Immunology and Laboratory Quality Control: A Comprehensive Review for Board Preparation, Certification and Clinical Practice. Elsevier 2014.
37.
Wei J, Yang L, Wu YN, Xu J. Serum miR-1290 and miR-1246 as potential diagnostic biomarkers of human pancreatic cancer. J Cancer 2020; 11: 1325-1333.
38.
Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 2013; 19: 3600-3610.
39.
Nagpal N, Kulshreshtha R. miR-191:an emerging player in disease biology. Front Genet 2014; 5: 99.
40.
Jiangqiao Z, Tianyu W, Zhongbao C, Long Z, Jilin Z, Xiaoxiong M, Tao Q. Ubiquitin-specific peptidase 10 protects against hepatic ischaemic/reperfusion injury via TAK1 signalling. Front Immunol 2020; 11: 506275.
41.
Liu H, Xu XF, Zhao Y, Tang MC, Zhou YQ, Lu J, Gao FH. MicroRNA-191 promotes pancreatic cancer progression by targeting USP10. Tumor Biol 2014; 35: 12157-12163.
42.
Yu S, Lu Y, Zong M, Tan Q, Fan L. Hypoxia-induced miR-191-C/EBP signaling regulates cell proliferation and apoptosis of fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Res Ther 2019; 21: 78.
43.
Date K, Satoh A, Iida K, Ogawa H. Pancreatic -amylase controls glucose assimilation by duodenal retrieval through N-glycan-specific binding, endocytosis, and degradation. J Biol Chem 2015; 290: 17439-17450.
44.
Dimitrova Kovacheva-Slavova M, Georgiev Getsov P, Borislavov Vladimirov G, Georgiev Vladimirov B. Up-To-Date View on the Clinical Manifestations and Complications of Chronic Pancreatitis. In: Pancreatitis. Intech- Open 2019.
45.
Oh HC, Kwon C Il, El Hajj II, Easler JJ, Watkins J, Fogel EL, McHenry L, Sherman S, Zimmerman MK, Lehman GA. Low serum pancreatic amylase and lipase values are simple and useful predictors to diagnose chronic pancreatitis. Gut Liver 2017; 11: 878-883.
46.
Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol 2018; 9: 754.
47.
Shakour N, Ruscica M, Hadizadeh F, Cirtori C, Banach M, Jamialahmadi T, Sahebkar A. Statins and C-reactive protein: in silico evidenceon direct interaction. Arch Med Sci 2020; 16: 1432-1439.
48.
Meher S, Mishra TS, Sasmal PK, Rath S, Sharma R, Rout B, Sahu MK. Role of biomarkers in diagnosis and prognostic evaluation of acute pancreatitis. J Biomarkers 2015; 2015: 519534.
49.
Weissman S, Takakura K, Eibl G, Pandol SJ, Saruta M. The diverse involvement of cigarette smoking in pancreatic cancer development and prognosis. Pancreas 2020; 49: 612-620.
50.
Momi N, Kaur S, Rachagani S, Ganti AK, Batra SK. Smoking and microRNA dysregulation: a cancerous combination. Trends Mol Med 2014; 20: 36-47.
51.
Matsuhashi S, Manirujjaman M, Hamajima H, Ozaki I. Control mechanisms of the tumor suppressor PDCD4: expression and functions. Int J Mol Sci 2019; 20: 2304.
52.
Goto T, Fujiya M, Konishi H, Sasajima J, Fujibayashi S, Hayashi A. An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker. BMC Cancer 2018; 18: 116.
53.
Wu ZH, Pfeffer LM. MicroRNA regulation of F-box proteins and its role in cancer. Semin Cancer Biol 2016; 36: 80-87.
54.
Wu MF, Yang J, Xiang T, Shi YY, Liu LJ. MiR-21 targets Fas ligand-mediated apoptosis in breast cancer cell line MCF-7. J Huazhong Univ Sci Technol Med Sci 2014; 34: 190-194.
55.
Karasek P, Gablo N, Hlavsa J, Kiss I, Vychytilova-Faltejskova P, Hermanova M, Kala Z, Slaby O, Prochazka V. Pre-operative plasma miR-21-5p is a sensitive biomarker and independent prognostic factor in patients with pancreatic ductal adenocarcinoma undergoing surgical resection. Cancer Genom Proteomics 2018; 15: 321-327.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
